ner1006
Colon Cancer
NorginePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 65/ 100
Competitive context
158 Active assets in the Colon Cancer cohort.
View all 50 →
Same molecule, other indications
ner1006 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →